Voyager doses first patient with anti-tau antibody in Alzheimer’s trial
The Phase Ia trial will evaluate the safety and efficacy of Voyager’s tau-targeting humanised IgG4 monoclonal antibody VY-TAU01.
The Phase Ia trial will evaluate the safety and efficacy of Voyager’s tau-targeting humanised IgG4 monoclonal antibody VY-TAU01.